TY - JOUR
T1 - Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-α and lipopolysaccharide
AU - Hartz, Anika M.S.
AU - Bauer, Björn
AU - Fricker, Gert
AU - Miller, David S.
PY - 2006
Y1 - 2006
N2 - At the blood-brain barrier, P-glycoprotein, an ATP-driven drug efflux pump, selectively limits drug access to the brain parenchyma, impeding pharmacotherapy of a number of central nervous system (CNS) disorders. We previously used confocal imaging to demonstrate in isolated rat brain capillaries that endothelin-1 (ET-1), acting through an ETB receptor, NO synthase, and protein kinase C, rapidly and reversibly reduces P-glycoprotein transport function. In this study, we define a link between the brain's innate immune response and functional regulation of P-glycoprotein. We show that exposing brain capillaries to the inflammatory cytokine tumor necrosis factor-α (TNF-α), activated a TNF-R1 receptor, released ET-1, activated ETB receptor signaling, and essentially abolished P-glycoprotein-mediated transport. Bacterial lipopolysaccharide, a potent activator of the brain's innate immune response, reduced P-glycoprotein activity through TNF-α release, ET-1 release, and ETB receptor signaling. TNF-α and LPS effects had a rapid onset (minutes), were reversible, and did not involve changes in tight junctional permeability. These findings define a signaling pathway through which P-glycoprotein activity is acutely modulated. They show that this key component of the selective/active blood-brain barrier is an early target of cytokine signaling during the innate immune response and suggest ways to manipulate the barrier for improved CNS pharmacotherapy.
AB - At the blood-brain barrier, P-glycoprotein, an ATP-driven drug efflux pump, selectively limits drug access to the brain parenchyma, impeding pharmacotherapy of a number of central nervous system (CNS) disorders. We previously used confocal imaging to demonstrate in isolated rat brain capillaries that endothelin-1 (ET-1), acting through an ETB receptor, NO synthase, and protein kinase C, rapidly and reversibly reduces P-glycoprotein transport function. In this study, we define a link between the brain's innate immune response and functional regulation of P-glycoprotein. We show that exposing brain capillaries to the inflammatory cytokine tumor necrosis factor-α (TNF-α), activated a TNF-R1 receptor, released ET-1, activated ETB receptor signaling, and essentially abolished P-glycoprotein-mediated transport. Bacterial lipopolysaccharide, a potent activator of the brain's innate immune response, reduced P-glycoprotein activity through TNF-α release, ET-1 release, and ETB receptor signaling. TNF-α and LPS effects had a rapid onset (minutes), were reversible, and did not involve changes in tight junctional permeability. These findings define a signaling pathway through which P-glycoprotein activity is acutely modulated. They show that this key component of the selective/active blood-brain barrier is an early target of cytokine signaling during the innate immune response and suggest ways to manipulate the barrier for improved CNS pharmacotherapy.
UR - http://www.scopus.com/inward/record.url?scp=31044447881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31044447881&partnerID=8YFLogxK
U2 - 10.1124/mol.105.017954
DO - 10.1124/mol.105.017954
M3 - Article
C2 - 16278373
AN - SCOPUS:31044447881
SN - 0026-895X
VL - 69
SP - 462
EP - 470
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 2
ER -